8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Ms. Tina Monahan
8.6
- - Patient Engagement
- - 8 weeks August - September 2023
- - Clinical Research Organization
Reviewed:
Impressive patient engagement strategies, significant improvement in recruitment rates.
The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.
Ms. Constance Schmitt III
9.2
- - Regulatory Strategy Consulting
- - 4 weeks July - August 2024
- - Biotech Startup
Reviewed:
Thorough and strategic regulatory strategy consulting.
The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.
Leah Dickinson
5.7
- - Project Management
- - 12 weeks March - May 2024
- - Biotech Company
Reviewed:
Poor communication and missed deadlines caused frustration.
Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.
Darin Welch
8.8
- - Companion Diagnostics Development
- - 16 weeks January - May 2024
- - Pharmaceutical Company
Reviewed:
High-quality companion diagnostics development, delivered on time.
The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.
Tyler MacGyver Jr.
9.2
- - Data Visualization
- - 3 weeks December 2023
- - Pharmaceutical Company
Reviewed:
Highly effective data visualization, easy to interpret and impactful.
The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.
Rex Blick
9
- - Clinical Protocol Design
- - 6 weeks April - May 2023
- - Pharmaceutical Company
Reviewed:
Comprehensive protocol design, very detailed and precise.
The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.
Marvin Hessel
6
- - Health Technology Assessment
- - 8 weeks July - September 2024
- - Pharmaceutical Company
Reviewed:
Health technology assessment was superficial, lacked thorough analysis.
The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.
Mr. Ross Bayer
6.5
- - Regulatory Submission
- - 8 weeks May - July 2024
- - Pharmaceutical Company
Reviewed:
Regulatory submission was incomplete, required additional work.
The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.
Kurt Huels
9.3
- - Project Management
- - 10 weeks July - September 2023
- - Biotech Company
Reviewed:
Seamless project management, results exceeded expectations.
Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.
Vickie Jakubowski
5.4
- - Process Development
- - 14 weeks June - September 2024
- - Biotech Company
Reviewed:
Process development project faced delays, communication issues.
The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.
